Johnson & Johnson on Saturday became the third developer of a COVID-19 vaccine to be granted an emergency use authorization (EUA) by the FDA, allowing patients to be dosed with the company’s Janssen COVID-19 vaccine candidate more than two months after the agency granted the first two.
The first four million doses of its Janssen COVID-19 vaccine are expected be distributed across the United States this week, with 100 million doses set to be delivered by the end of June. Unlike Pfizer and BioNTech’s BNT162b2, which received an EUA on December 11, and Moderna’s mRNA-1273, which was authorized for emergency use a week later, J&J’s vaccine requires only a single dose.
Top 7 Best Selling COVID-19 Vaccines and Drugs of 2020
Source: Andriy Onufriyenko/Getty Images
Pandemic’s first authorized therapeutics generated $4B last year, with up to $38.5B forecast for 2021
February 25, 2021
A year into the COVID-19 pandemic, the first authorized drugs and vaccines indicated for the virus have generated more than a combined $4.23 billion for their developers. [Andriy Onufriyenko / Getty Images]
Share
A year into the COVID-19 pandemic, the first authorized drugs and vaccines indicated for the virus have generated more than a combined $4.23 billion for their developers, according to sales figures released in recent weeks by developers of the therapeutics.
Those developers have set the stage for a potentially much more lucrative 2021, based on forecasts released by Wall Street watchers of the biopharma industry.